Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Do we need an early unfavorable (intermediate) stage of Hodgkin's lymphoma?

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. High intratumoural galectin-1 expression predicts adverse outcome in ALK- ALCL and CD30+ PTCL-NOS

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. PD-L1 expression is low in large B-cell lymphoma with MYC or double-hit translocation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
The outcome of patients who have early unfavorable or intermediate-stage Hodgkin's lymphoma has greatly improved. The increasing efficacy of chemotherapy and late toxic effects of wide-field radiotherapy justify the careful testing of the new involved-node radiotherapy principle in the combined-modality approach. For the purpose of tailoring treatment to the individual patient we need more accurate measures, preferably predictive factors that may tell us how the individual patient should be treated. The result of an early positron emission tomography scan with fluorodeoxyglucose may well become the major new treatment-related guidance for an individually tailored treatment approach.
OriginalsprogEngelsk
TidsskriftHematology / Oncology Clinics of North America
Vol/bind21
Udgave nummer5
Sider (fra-til)881-96
Antal sider16
ISSN0889-8588
DOI
StatusUdgivet - 1 okt. 2007

ID: 32265562